[{"id":"0c99b6bb-e3ca-4df7-a9e1-804320717c79","acronym":"","url":"https://clinicaltrials.gov/study/NCT01252628","created_at":"2021-01-18T05:02:55.396Z","updated_at":"2024-07-02T16:37:10.731Z","phase":"Phase 1/2","brief_title":"Phase 1 and 2 Study of PX-866 and Cetuximab","source_id_and_acronym":"NCT01252628","lead_sponsor":"Cascadian Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • sonolisib (PX 866)"],"overall_status":"Completed","enrollment":" Enrollment 178","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 01/01/2014","study_completion_date":" 01/01/2014","last_update_posted":"2018-05-16"}]